The FDA creates a quicker path for gene therapies

The FDA creates a quicker path for gene therapies

The Food and Drug Administration aims to evaluate treatments for rare diseases based on plausible evidence that they would work — without requiring a clinical trial first.

Gene editing takes centre stage in FDA’s new rare disease approval pathway

The aim of the pathway is to remove red tape for bespoke therapies designed for patients with rare diseases.The post Gene editing takes centre stage in FDA’s new rare disease approval pathway appeared first on Clinical Trials Arena.

How will FDA speed approval of gene therapies?

New regulatory route aims to shorten timelines for rare therapies The agency has adopted guidance that allows some gene based treatments for rare diseases to be evaluated on a lower evidentiary threshold than traditional approval pathways. Instead of requiring large randomized clinical trials up…

The FDA creates a quicker path for gene therapies - TPR: The Public's Radio

The Food and Drug Administration aims to evaluate treatments for rare diseases based on plausible evidence that they would work — without requiring a clinical trial first. The post The FDA creates a quicker path for gene therapies appeared first on TPR: The Public's Radio.